<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37296110</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Persistent serum protein signatures define an inflammatory subcategory of long COVID.</ArticleTitle><Pagination><StartPage>3417</StartPage><MedlinePgn>3417</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3417</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-38682-4</ELocationID><Abstract><AbstractText>Long COVID or post-acute sequelae of SARS-CoV-2 (PASC) is a clinical syndrome featuring diverse symptoms that can persist for months following acute SARS-CoV-2 infection. The aetiologies may include persistent inflammation, unresolved tissue damage or delayed clearance of viral protein or RNA, but the biological differences they represent are not fully understood. Here we evaluate the serum proteome in samples, longitudinally collected from 55 PASC individuals with symptoms lasting &#x2265;60 days after onset of acute infection, in comparison to samples from symptomatically recovered SARS-CoV-2 infected and uninfected individuals. Our analysis indicates heterogeneity in PASC and identified subsets with distinct signatures of persistent inflammation. Type II interferon signaling and canonical NF-&#x3ba;B signaling (particularly associated with TNF), appear to be the most differentially enriched signaling pathways, distinguishing a group of patients characterized also by a persistent neutrophil activation signature. These findings help to clarify biological diversity within PASC, identify participants with molecular evidence of persistent inflammation, and highlight dominant pathways that may have diagnostic or therapeutic relevance, including a protein panel that we propose as having&#xa0;diagnostic utility for differentiating inflammatory and non-inflammatory PASC.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Talla</LastName><ForeName>Aarthi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Vasaikar</LastName><ForeName>Suhas V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Seagen, Bothell, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szeto</LastName><ForeName>Gregory Lee</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Seagen, Bothell, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemos</LastName><ForeName>Maria P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czartoski</LastName><ForeName>Julie L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacMillan</LastName><ForeName>Hugh</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3661-2212</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moodie</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-8701-2001</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Kristen W</ForeName><Initials>KW</Initials><Identifier Source="ORCID">0000-0002-8901-9941</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Moderna, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Lamar B</ForeName><Initials>LB</Initials><Identifier Source="ORCID">0000-0002-6180-5545</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomson</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-3861-9998</Identifier><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Lynne A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0003-1541-4655</Identifier><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coffey</LastName><ForeName>Ernest M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Rosa</LastName><ForeName>Stephen C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Evan W</ForeName><Initials>EW</Initials><Identifier Source="ORCID">0000-0002-2889-243X</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skene</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaojun</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-0832-9479</Identifier><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bumol</LastName><ForeName>Thomas F</ForeName><Initials>TF</Initials><Identifier Source="ORCID">0000-0003-4319-1006</Identifier><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA. tbumol@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juliana McElrath</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. jmcelrat@fredhutch.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torgerson</LastName><ForeName>Troy R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0003-3489-5036</Identifier><AffiliationInfo><Affiliation>Allen Institute for Immunology, Seattle, WA, USA. troy.torgerson@alleninstitute.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UM1 AI068618</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068635</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI069481</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>A.T., S.V.V., G.L.S., T.R.T., P.J.S., X.L., and T.F.B. have a provisional patent on protein signatures in Long COVID (Application PCT/US2022/026841). The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>15</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37296110</ArticleId><ArticleId IdType="pmc">PMC10252177</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-38682-4</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-38682-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groff D, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw. Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. PASCLex: A comprehensive post-acute sequelae of COVID-19 (PASC) symptom lexicon derived from electronic health record clinical notes. J. Biomed. Inform. 2022;125:103951. doi: 10.1016/j.jbi.2021.103951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2021.103951</ArticleId><ArticleId IdType="pmc">PMC8590503</ArticleId><ArticleId IdType="pubmed">34785382</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevinsky JR, et al. Late Conditions Diagnosed 1-4 Months Following an Initial Coronavirus Disease 2019 (COVID-19) Encounter: A Matched-Cohort Study Using Inpatient and Outpatient Administrative Data-United States, 1 March-30 June 2020. Clin. Infect. Dis. 2021;73:S5&#x2013;S16. doi: 10.1093/cid/ciab338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab338</ArticleId><ArticleId IdType="pmc">PMC8135331</ArticleId><ArticleId IdType="pubmed">33909072</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell ML, et al. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. PLoS One. 2021;16:e0254347. doi: 10.1371/journal.pone.0254347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254347</ArticleId><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehar, S., Boushra, M., Ntiamoah, P. &amp; Biehl, M. Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the &#x201c;long-haulers.&#x201d; CCJM10.3949/ccjm.88a.21010-up (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34625436</ArticleId></ArticleIdList></Reference><Reference><Citation>Horberg MA, et al. Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. Nat. Commun. 2022;13:1&#x2013;13. doi: 10.1038/s41467-022-33573-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33573-6</ArticleId><ArticleId IdType="pmc">PMC9556630</ArticleId><ArticleId IdType="pubmed">36224218</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, et al. Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. BMC Med. 2022;20:50. doi: 10.1186/s12916-021-02222-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02222-y</ArticleId><ArticleId IdType="pmc">PMC8813480</ArticleId><ArticleId IdType="pubmed">35114994</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, J. et al. Distinguishing features of Long COVID identified through immune profiling. bioRxiv10.1101/2022.08.09.22278592 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda, A. et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. bioRxiv10.1101/2022.01.07.475453 (2022).</Citation></Reference><Reference><Citation>Working WHO. Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 2020;20:e192&#x2013;e197. doi: 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir. Med. 2021;9:1275&#x2013;1287. doi: 10.1016/S2213-2600(21)00383-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H. et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nature Medicine10.1038/s41591-022-02116-3 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WC. Selecting diagnostic tests for ruling out or ruling in disease: the use of the Kullback-Leibler distance. Int. J. Epidemiol. 1999;28:521&#x2013;525. doi: 10.1093/ije/28.3.521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/28.3.521</ArticleId><ArticleId IdType="pubmed">10405859</ArticleId></ArticleIdList></Reference><Reference><Citation>Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5:e13984. doi: 10.1371/journal.pone.0013984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013984</ArticleId><ArticleId IdType="pmc">PMC2981572</ArticleId><ArticleId IdType="pubmed">21085593</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield KM, et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. 2022;18:e1010359. doi: 10.1371/journal.ppat.1010359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. 2021;224:1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Menezes AS, Jr, Botelho SM, Santos LR, Rezende AL. Acute COVID-19 Syndrome Predicts Severe Long COVID-19: An Observational Study. Cureus. 2022;14:e29826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9527039</ArticleId><ArticleId IdType="pubmed">36204261</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat. Commun. 2021;12:6571. doi: 10.1038/s41467-021-26513-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26513-3</ArticleId><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>European Cenre for Disease Prevention and Control. Prevalence of post COVID-19 condition symptoms: a systematic review and meta-analysis of cohort study data, stratified by recruitment setting. ECDC (2022).</Citation></Reference><Reference><Citation>Klevebro S, et al. Inflammation-related plasma protein levels and association with adiposity measurements in young adults. Sci. Rep. 2021;11:11391. doi: 10.1038/s41598-021-90843-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90843-x</ArticleId><ArticleId IdType="pmc">PMC8166979</ArticleId><ArticleId IdType="pubmed">34059769</ArticleId></ArticleIdList></Reference><Reference><Citation>Figarska SM, et al. Proteomic profiles before and during weight loss: Results from randomized trial of dietary intervention. Sci. Rep. 2020;10:7913. doi: 10.1038/s41598-020-64636-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-64636-7</ArticleId><ArticleId IdType="pmc">PMC7220904</ArticleId><ArticleId IdType="pubmed">32404980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Cate V, et al. A targeted proteomics investigation of the obesity paradox in venous thromboembolism. Blood Adv. 2021;5:2909&#x2013;2918. doi: 10.1182/bloodadvances.2020003800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003800</ArticleId><ArticleId IdType="pmc">PMC8341360</ArticleId><ArticleId IdType="pubmed">34309635</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulop, T. et al. Immunology of Aging: the Birth of Inflammaging. Clin. Rev. Allergy Immunol. 10.1007/s12016-021-08899-6 (2021) .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449217</ArticleId><ArticleId IdType="pubmed">34536213</ArticleId></ArticleIdList></Reference><Reference><Citation>Moaddel R, et al. Proteomics in aging research: A roadmap to clinical, translational research. Aging Cell. 2021;20:e13325. doi: 10.1111/acel.13325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13325</ArticleId><ArticleId IdType="pmc">PMC8045948</ArticleId><ArticleId IdType="pubmed">33730416</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. 2005;102:15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbin MR, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep. Med. 2021;2:100287. doi: 10.1016/j.xcrm.2021.100287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100287</ArticleId><ArticleId IdType="pmc">PMC8091031</ArticleId><ArticleId IdType="pubmed">33969320</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez L, et al. Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. Cell Rep. Med. 2020;1:100078. doi: 10.1016/j.xcrm.2020.100078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100078</ArticleId><ArticleId IdType="pmc">PMC7405891</ArticleId><ArticleId IdType="pubmed">32838342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CCL, et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022;71:226&#x2013;229. doi: 10.1136/gutjnl-2021-324280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763. doi: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank, Z., Senussi, Y., Alter, G. &amp; Walt, D. R. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. 10.1101/2022.06.14.22276401 (2022).</Citation></Reference><Reference><Citation>Toufiq M, et al. Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data. Immunology. 2020;161:291&#x2013;302. doi: 10.1111/imm.13239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13239</ArticleId><ArticleId IdType="pmc">PMC7692248</ArticleId><ArticleId IdType="pubmed">32682335</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;lin C, Movitz C, Lundqvist H, Dahlgren C. Translocation of annexin XI to neutrophil subcellular organelles. Biochim. Biophys. Acta. 1997;1326:149&#x2013;156. doi: 10.1016/S0005-2736(97)00018-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0005-2736(97)00018-7</ArticleId><ArticleId IdType="pubmed">9188810</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebratti T, et al. A sustained type I IFN-neutrophil-IL-18 axis drives pathology during mucosal viral infection. Elife. 2021;10:e65762. doi: 10.7554/eLife.65762.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65762</ArticleId><ArticleId IdType="pmc">PMC8163503</ArticleId><ArticleId IdType="pubmed">34047696</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183:1479&#x2013;1495.e20. doi: 10.1016/j.cell.2020.10.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.037</ArticleId><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf;, C. et al. From online data collection to identification of disease mechanisms: The IL-1&#xdf;, IL-6 and TNF-&#x3b1; cytokine triad is associated with post-acute sequelae of COVID-19 in a digital research cohort. bioRxiv10.1101/2021.11.16.21266391 (2021).</Citation></Reference><Reference><Citation>Asano, T. et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 6, eabl4348 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8532080</ArticleId><ArticleId IdType="pubmed">34413140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol.6, eabl4340 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q. et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J. Exp. Med. 219, e20220131 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9206114</ArticleId><ArticleId IdType="pubmed">35708626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen KW, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep. Med. 2021;2:100354. doi: 10.1016/j.xcrm.2021.100354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100354</ArticleId><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 2015;67:1&#x2013;48. doi: 10.18637/jss.v067.i01.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatatos L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021 Mar 25;372:1413-1418. 10.1126/science.abg9175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139425</ArticleId><ArticleId IdType="pubmed">33766944</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton H, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J. Immunol. Methods. 2007;323:39&#x2013;54. doi: 10.1016/j.jim.2007.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2683732</ArticleId><ArticleId IdType="pubmed">17451739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dintwe O, et al. Corrigendum: OMIP-056: Evaluation of Human Conventional T Cells, Donor-Unrestricted T Cells, and NK Cells Including Memory Phenotype by Intracellular Cytokine Staining. Cytom. A. 2020;97:199&#x2013;201. doi: 10.1002/cyto.a.23962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.23962</ArticleId><ArticleId IdType="pmc">PMC8094202</ArticleId><ArticleId IdType="pubmed">31989802</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, et al. Mixture models for single-cell assays with applications to vaccine studies. Biostatistics. 2014;15:87&#x2013;101. doi: 10.1093/biostatistics/kxt024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxt024</ArticleId><ArticleId IdType="pmc">PMC3862207</ArticleId><ArticleId IdType="pubmed">23887981</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton MA, Kendziorski CM, Richmond CS, Blattner FR, Tsui KW. On differential variability of expression ratios: improving statistical inference about gene expression changes from microarray data. J. Comput. Biol. 2001;8:37&#x2013;52. doi: 10.1089/106652701300099074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/106652701300099074</ArticleId><ArticleId IdType="pubmed">11339905</ArticleId></ArticleIdList></Reference><Reference><Citation>McClish DK. Analyzing a Portion of the ROC Curve. Med. Decis. Mak. 1989;9:190&#x2013;195. doi: 10.1177/0272989X8900900307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X8900900307</ArticleId><ArticleId IdType="pubmed">2668680</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd LE, Pepe MS. Partial AUC estimation and regression. Biometrics. 2003;59:614&#x2013;623. doi: 10.1111/1541-0420.00071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1541-0420.00071</ArticleId><ArticleId IdType="pubmed">14601762</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat. Protoc. 2019;14:482&#x2013;517. doi: 10.1038/s41596-018-0103-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-018-0103-9</ArticleId><ArticleId IdType="pmc">PMC6607905</ArticleId><ArticleId IdType="pubmed">30664679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie, T., Friedman, J. &amp; Tibshirani, R. The Elements of Statistical Learning. (Springer New York).</Citation></Reference><Reference><Citation>Talla A. et al. Persistent serum protein signatures define an inflammatory subset of long COVID. Zenodo, 10.5281/zenodo.7872791.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>